{"id":"exantide-with-dapagliflozin","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"10–20","effect":"Vomiting"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"10–15","effect":"Genital mycotic infections"},{"rate":"5–10","effect":"Urinary tract infection"},{"rate":"5–15","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exenatide activates GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion and suppress glucagon release. Dapagliflozin inhibits sodium-glucose cotransporter 2 in the proximal renal tubule, promoting urinary glucose excretion independent of insulin. This dual mechanism addresses hyperglycemia through both insulin-dependent and insulin-independent pathways.","oneSentence":"Exenatide (a GLP-1 receptor agonist) stimulates insulin secretion and reduces glucagon, while dapagliflozin (an SGLT2 inhibitor) increases urinary glucose excretion, together improving glycemic control through complementary pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:33.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02229396","phase":"PHASE3","title":"Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-04","conditions":"Diabetes Mellitus","enrollment":695}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4143,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Exantide with Dapagliflozin","genericName":"Exantide with Dapagliflozin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exantide with Dapagliflozin is a combination treatment being studied for the condition of Diabetes Mellitus. Dapagliflozin, a small molecule sodium/glucose cotransporter 2 inhibitor, is part of this combination treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}